Article
Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers.
Nature communications - 9 Aug 2016
Miller Christopher A, Gindin Yevgeniy, Lu Charles, Griffith Obi L, Griffith Malachi, Shen Dong, Hoog Jeremy, Li Tiandao, Larson David E, Watson Mark, Davies Sherri R, Hunt Kelly, Suman Vera J, Snider Jacqueline, Walsh Thomas, Colditz Graham A, DeSchryver Katherine, Wilson Richard K, Mardis Elaine R, Ellis Matthew J
Abstract excerpt
Resistance to oestrogen-deprivation therapy is common in oestrogen-receptor-positive (ER+) breast cancer. To better understand the contributions of tumour heterogeneity and evolution to resistance, here we perform comprehensive genomic characterization of 22 primary tumours sampled before and after 4 months of neoadjuvant aromatase inhibitor (NAI) treatment. Comparing whole-genome sequencing of tumour/normal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.